Previous studies investigating therapeutic benefits of dehydrocrenatidine have demonstrated that this natural plant compound acts as a specific inhibitor of the JAK2 signaling pathway and that it inhibits the growth of breast and prostate cancer cells by targeting the JAK–STAT pathway [14]. Here, JAK2 is linked to prostate carcinoma.